Syndax Highlights Durable Remissions For Revumenib In Acute Leukemia Patients

  • Syndax Pharmaceuticals Inc SNDX announced updated data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin (NPM1) mutant and mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias. 
  • As of the March 2022 data cutoff date, sixty patients were efficacy evaluable. The overall response rate (ORR) was 53% (32/60), with a CR/CRh rate of 30% (18/60).
  • There were no discontinuations due to treatment-related adverse events, and the median duration of response was 9.1 months.
  • Revumenib was well-tolerated, and no new safety signals were identified in the trial.
  • Across evaluable patients with mNPM1 (n=14) or MLLr (n=46) acute leukemia who received revumenib, 12 (20%) patients proceeded to stem cell transplant, ten (83%) of whom were minimal residual disease-negative. 
  • Nine of the 12 patients (75%) who received a stem cell transplant remained in remission, with a median follow-up of 12.3 months, and four patients experienced remission for longer than one year. 
  • Three patients were treated in the compassionate use setting with revumenib maintenance following stem cell transplant or non-myeloablative stem cell boost, two (67%) remaining in remission for over one year.
  • Price Action: SNDX shares are up 2.14% at $23.38 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!